|

Rituximab Injection Clinical Trials

3 actively recruiting trials

Also known as: IDEC-C2B8

Pipeline

Early 1: 1Phase 3: 2

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Canadian Cancer Trials Group1
  • BeBetter Med Inc1

Indications

  • Cancer3
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma1
  • Lymphoma, B-Cell1
  • Diffuse Large B-Cell Lymphoma1

Other3 trials

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Phase 3
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Early 1
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.